Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) – Research analysts at Piper Sandler cut their FY2022 earnings per share estimates for Jounce Therapeutics in a research note issued on Wednesday, March 2nd. Piper Sandler analyst E. Tenthoff now anticipates that the company will earn ($2.63) per share for the year, down from their prior estimate […]